One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using one, ...

Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand. Overall, the GLP-1 market is expected to experience annual growth ...

Financing led by BVF Partners LP, with participation from new investors RA Capital Management, Cormorant Asset Management, Soleus Capital and existing investors aMoon Fund and Blackstone Multi-Asset ...

Hims & Hers aims to capitalize on the shortages of the branded drugs Wegovy and Zepbound. Read more to see why I'm bullish on ...

According to AltruBio, the new lead prospect has shown improved potency in down-regulating chronic pathogenic T cells in ...

You've watched others shed pounds in a matter of weeks after taking one of the new blockbuster weight-loss drugs, so you ...

Eli Lilly (NYSE:LLY) has secured China approval for its blockbuster drug tirzepatide for use in treating diabetes.

The most watched video, which was about the glucagon-like peptide 1 receptor agonist semaglutide, was watched almost a million times. "The growing obesity epidemic, particularly among young people, ...

The researchers found that 358,075 of 1.7 million individuals were dispensed antidepressants, and 8,495 of the 24,783 dispensed a GLP-1 receptor agonist were also dispensed an antidepressant in 2022 ...

Vamorolone (Agamree) is a first-in-class corticosteroid to treat Duchenne muscular dystrophy (DMD) in patients 2 years and older.

About 4 in 10 people who use GLP-1 agonist drugs do so mainly for weight loss, not to treat diabetes, a new study finds.

Patients taking semaglutide for a year saw significant improvements in exercise capacity and lost 2.9% more body weight ...